This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 17126 results found since Jan 2013.
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Overall and Demographic Subgroup Incidences of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis in the United States
Source: Journal of the American Academy of Dermatology - September 8, 2023 Category: Dermatology Authors: Inkyu E. Kang, Andrew Strunk, Amit Garg Source Type: research
Refractory Folliculitis Decalvans Treatment Success with a Novel Surgical Excision Approach Using Guarded High-Tension Sutures
CONCLUSION: Surgical excision with second-intention healing aided by guarded high-tension sutures effectively treated small and extensive FD lesions with no recurrence at long-term follow-up. To our knowledge, this is the first report of successful surgical treatment of FD.PMID:37675182 | PMC:PMC10478779 | DOI:10.2147/CCID.S422077
Source: Clinical, Cosmetic and Investigational Dermatology - September 7, 2023 Category: Dermatology Authors: Sanusi Umar Ade Waterman Donna Ton Paul Shitabata Source Type: research
Could red and near-infrared emitting fabric technology improve the severity of psoriasis, polymorphous light eruption, and alopecia areata?
CONCLUSION: Use of a wellness apparel that emits red and NIR light may be associated with improved disease severity in patients with mild elbow psoriasis, PMLE, and limited AA. Limitations of this study include continuation on topical, intralesional, or systemic medications and small sample size.PMID:37674258 | DOI:10.1080/09546634.2023.2251619
Source: Journal of Dermatological Treatment - September 6, 2023 Category: Dermatology Authors: Jessica N Pixley Rithi J Chandy Irma Richardson Joseph L Jorizzo Steven R Feldman Source Type: research
Utilization of Topical Ruxolitinib in Dermatology Utilization of Topical Ruxolitinib in Dermatology
This review summarizes the use of topical ruxolitinib, a JAK inhibitor, in various dermatological conditions including vitiligo, alopecia areata, atopic dermatitis, psoriasis, and more.Skin Therapy Letter
Source: Medscape Allergy Headlines - September 4, 2023 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Linear alopecia areata: an uncommon clinical variant. Presentation of 3 cases and review of the literature
Actas Dermosifiliogr. 2023 Aug 31:S0001-7310(23)00681-6. doi: 10.1016/j.ad.2023.01.020. Online ahead of print.NO ABSTRACTPMID:37659470 | DOI:10.1016/j.ad.2023.01.020
Source: Actas Dermo-Sifiliograficas - September 2, 2023 Category: Dermatology Authors: J Piquero-Casals D Morgado-Carrasco D Saceda-Corralo C Pe ña-Penabad Source Type: research
Prenatal diagnosis of lanosterol synthase deficiency: Fetal ultrasound findings as a window on family genetics
Eur J Med Genet. 2023 Aug 31:104825. doi: 10.1016/j.ejmg.2023.104825. Online ahead of print.ABSTRACTCholesterol is essential in the brain from the earliest stages of embryonic development. Disruption of cholesterol synthesis pathways that leads to cholesterol deficiency underlies a few syndromes, including desmosterolosis and Smith-Lemli-Opitz syndrome. In both syndromes, brain anomalies can occur. The LSS gene encodes lanosterol synthase (LSS), an important enzyme in the cholesterol biosynthesis pathway. Biallelic pathogenic variants in this gene cause alopecia-intellectual disability type 4 syndrome (APMR4, MIM 618840), ...
Source: European Journal of Medical Genetics - September 2, 2023 Category: Genetics & Stem Cells Authors: Sigal Matza Porges Hagar Mor-Shaked Avraham Shaag Shay Porat Hagit Daum Source Type: research
Linear alopecia areata: an uncommon clinical variant. Presentation of 3 cases and review of the literature
Actas Dermosifiliogr. 2023 Aug 31:S0001-7310(23)00681-6. doi: 10.1016/j.ad.2023.01.020. Online ahead of print.NO ABSTRACTPMID:37659470 | DOI:10.1016/j.ad.2023.01.020
Source: Actas Dermo-Sifiliograficas - September 2, 2023 Category: Dermatology Authors: J Piquero-Casals D Morgado-Carrasco D Saceda-Corralo C Pe ña-Penabad Source Type: research
